Houston's 2022 DEI Champions share obstacles they are overcoming promoting equitable innovation

EAVESDROPPING AT THE HOUSTON INNOVATION AWARDS GALA

These five individuals are up for the DEI Champion award this week. Here's what challenges they are facing promoting an equitable innovation ecosystem. Photos courtesy

As one of the most diverse cities in the world, Houston's business and innovation community has a unique opportunity to prioritize not just its diverse population, but also to make sure the city has equitable and inclusive opportunities.

Five Houstonians have been named finalists in the DEI Champion category for the Houston Innovation Awards Gala, which will be held on November 9. They shared some of the challenges they are facing as they fight to make sure Houston has an equitable innovation ecosystem.

"I have always been the only Black women in all of my engineering roles, and I worked so hard to get there and quite often feel so uncomfortable in this space. So, individuals who question my name don't always understand the important of someone expressing that I see you to an individual can mean. However, this is a challenge I am willing to face because I am changing people lives and these lives I am changing will impact the world."

Photo courtesy

— Kara Branch, founder and CEO of Black Girls Do Engineer Corp. "Although I believed in myself and that girls that look like me needed that representation and someone to mentor them and expose them to S.T.E.M., I had no one to do this for me, so I had to do this for girls in my community," she says. "I have faced some people who fight me about my name, but my name had to be my name because I needed to let Black girls know I was talking to them."

"You can’t expect to make an impact, big or small, if you’re not willing to meet people where they are. One challenge we’ve seen when it comes to talking about and implementing DEI programs within the organization is that not everyone has the same understanding of what diversity, equity, and inclusion is."

Photo courtesy

Arianne Dowdell, vice president and chief diversity, equity and inclusion officer for Houston Methodist. "Another challenge we see is that sometimes people expect to see change immediately," she continues. "This is a journey not a race, and if done right, it’s something that will continue to evolve and grow."

"Nobody wants to be tagged as difficult or uncomfortable to be with. A lot of bystanders will also make a calculated risk when witnessing bias, what is in it for me? Many will turn a blind eye if there are other interests at play."

Photo courtesy

— Juliana Garaizar, head of Houston incubator for Greentown Labs and lead investor for Portfolia. Garaizar explains that she sees people afraid of facing the repercussions that come with speaking up or standing up to bias and harassment.

"Sustainable funding. We have the talent, the access to mentors and STEM education/activities and preparation workshops and certifications. But not having the capital to hire and effectively manage this growth has been very challenging to where we've had to say no to expansion (girls in need) and and increase in girls within our yearlong and skill-building programs."

Photo courtesy

— Loretta Williams Gurnell, founder of SUPERGirls SHINE Foundation. She continues, "However, because we are serious in creating a diverse and sustained pipeline for more underserved girls (women) in STEM, we heavily rely on organizations that are like-minded in practices and core values to partner with and provide our services and opportunities to their girls and vice versus. It builds community and sustainability for all who are involved."

"The problems we face are so daunting and overwhelming that it can be hard to know where to start. ... At some point I realized that you just have to start somewhere, and you have to go deep in one area." 

Photo courtesy

— Rob Schapiro, director of Microsoft's Energy Acceleration Program. "Only 27 percent of STEM workers are women. A mere 2 percent of venture capital money goes to women and far less to black women. The average wealth of the top 5 percent of White American households is seven times more than the average of the top 5 percent of Black households. These kinds of statistics can paralyze you into inaction," he explains. "It is great to be an ally to all, but you can have more impact if you focus your attention and efforts on a specific area. What is challenging still is that you will want to do more and spread your efforts, but you have to stay disciplined. One person cannot fix everything. But, using your privilege and your network you can influence many others and through them make a huge impact."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”